EUFOREA treatment algorithm for allergic rhinitis

P. W. Hellings, G. Scadding, C. Bachert, L. Bjermer, G. W. Canonica, L. O. Cardell, A. S. Carney, J. Constantinidis, L. Deneyer, Z. Diamant, S. Durham, P. Gevaert, R. Harvey, C. Hopkins, A. Kjeldsen, L. Klimek, V. J. Lund, D. Price, J. Rimme, D. RyanG. Roberts, P. Sahlstrand-Johnson, S. Salmi, M. Samji, Guy Scadding, P. Smith, A. Steinsvik, M. Wagenmann, S. Seys, U. Wahn, W. J. Fokkens

Research output: Contribution to journalLetterpeer-review

31 Citations (Scopus)
341 Downloads (Pure)

Abstract

To the Editor:
Allergic rhinitis (AR) is the most common chronic inflammatory disease, affecting an estimated 100 million Europeans (1).Despite a substantial burden on individuals, society and health economies (2), AR remains under-diagnosed, under-estimated (in terms of severity), and under-treated (3). Although effective and safe treatments exist, patients wait too long to seek medical advice, often preferring to self-manage at drug stores and at the pharmacy.
Original languageEnglish
Pages (from-to)618-622
Number of pages5
JournalRhinology
Volume58
Issue number6
DOIs
Publication statusPublished - 2020

Keywords

  • Allergic rhinitis
  • European Forum for Research & Education in Allergy & Airway Diseases (EUFOREA)
  • treatment algorithm

Fingerprint

Dive into the research topics of 'EUFOREA treatment algorithm for allergic rhinitis'. Together they form a unique fingerprint.

Cite this